This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Principal Investigator
Anne-Marie Langevin
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu
Arm | Description | Intervention |
---|---|---|
Arm A (chemotherapy, HSCT, EBRT) | See Arm A in detailed description. | Undergo autologous HSCT Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
|
Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT) | See Arm C in detailed description. Closed to accrual as of 12/17/20. | Undergo autologous HSCT Other names:
Given IV Other names:
Given IV Other names:
|
Arm E (crizotinib, chemotherapy, HSCT, EBRT) | See Arm E in detailed description. | Undergo autologous HSCT Other names:
Given IV Other names:
Given PO Other names:
Given IV Other names:
Given IV Other names:
|
Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT) | See Arm B in detailed description. | Undergo autologous HSCT Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
|
Arm D (chemotherapy, HSCT, EBRT) | See Arm D in detailed description. | Undergo autologous HSCT Other names:
Given IV Other names:
Given IV Other names:
Given IV Other names:
|